[1] |
Setta⁃Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis⁃associated pustular phenotypes[J]. J Invest Dermatol, 2013,133(5):1366⁃1369. doi: 10.1038/jid.2012.490
|
[2] |
Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies[J]. Clin Rev Allergy Immunol, 2018,54(1):102⁃113. doi: 10.1007/s12016⁃018⁃8668⁃1.
|
[3] |
Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52⁃week, open⁃label, phase 3 study (UNCOVER⁃J)[J]. J Dermatol, 2017,44(4):355⁃362. doi: 10.1111/1346⁃8138.13622.
|
[4] |
Okubo Y, Mabuchi T, Iwatsuki K, et al. Long⁃term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open⁃label, phase 3 study (UNCOVER⁃J)[J]. J Eur Acad Dermatol Venereol, 2019,33(2):325⁃332. doi: 10.1111/jdv.15287.
|
[5] |
Miller AC, Holland TE, Cohen DJ. Treatment of acrodermatitis continua of hallopeau with ixekizumab[J]. J Dermatolog Treat, 2021,32(1):117⁃119. doi: 10.1080/09546634.2019.1628170.
|
[6] |
Pilz AC, Roenneberg S, Biedermann T, et al. Ixekizumab for acrodermatitis continua[J]. J Dtsch Dermatol Ges, 2018,16(7):907⁃910. doi: 10.1111/ddg.13568.
|
[7] |
Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52⁃week analysis from phase III open⁃label multicenter Japanese study[J]. J Dermatol, 2016,43(9):1011⁃1017. doi: 10.1111/1346⁃8138.13306.
|
[8] |
Wilsmann⁃Theis D, Schnell LM, Ralser⁃Isselstein V, et al. Successful treatment with interleukin⁃17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations[J]. J Dermatol, 2018,45(7):850⁃854. doi: 10.1111/1346⁃8138.14318.
|
[9] |
Nishida M, Takeichi T, Kono M, et al. Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis[J]. J Dermatol, 2020,47(3):e77⁃77e78. doi: 10.1111/1346⁃8138.15228.
|
[10] |
Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work[J]. J Dermatol, 2018,45(11):1353⁃1356. doi: 10.1111/1346⁃8138.14636.
|
[11] |
Molho⁃Pessach V, Alyan R, Gordon D, et al. Secukinumab for the treatment of deficiency of interleukin 36 receptor antagonist in an adolescent[J]. JAMA Dermatol, 2017,153(5):473⁃475. doi: 10.1001/jamadermatol.2016.5705.
|
[12] |
Liu N, Zhu L, Cheng Y, et al. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report[J]. Acta Derm Venereol, 2020,100(15):adv00251. doi: 10.2340/ 00015555⁃3611.
|
[13] |
Balestri R, Rech G, Tasin L, et al. Acrodermatitis continua of Hallopeau successfully treated with secukinumab[J]. J Dermatolog Treat, 2018,29(sup1):3⁃5. doi: 10.1080/09546634. 2018.1527993.
|
[14] |
Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab[J]. JAAD Case Rep, 2017,3(3):215⁃218. doi: 10.1016/j.jdcr.2017.02.016.
|
[15] |
Smirnova LM, Vertieva EY, Olisova OY, et al. Outcomes of various types of therapy in patients with treatment⁃resistant acrodermatitis continua of Hallopeau[J]. Biologics, 2019,13:83⁃87. doi: 10.2147/BTT.S199100.
|
[16] |
Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial[J]. J Am Acad Dermatol, 2017,76(1):70⁃80. doi: 10.1016/j.jaad.2016.07.058.
|
[17] |
Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52⁃week, open⁃label study[J]. Br J Dermatol, 2017,176(3):741⁃751. doi: 10.1111/bjd. 14702.
|
[18] |
Passante M, Dastoli S, Nisticò SP, et al. Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: a case report[J]. Dermatol Ther, 2020,33(1):e13170. doi: 10.1111/dth. 13170.
|
[19] |
Nakao M, Asano Y, Kamata M, et al. Successful treatment of palmoplantar pustular psoriasis with brodalumab[J]. Eur J Dermatol, 2018,28(4):538⁃539. doi: 10.1684/ejd.2018.3325.
|
[20] |
Pinter A, Wilsmann⁃Theis D, Peitsch WK, et al. Interleukin⁃17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases[J]. J Dermatol, 2019,46(5):426⁃430. doi: 10.1111/1346⁃8138.14815.
|
[21] |
Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin⁃23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52⁃week, phase 3, multicenter, open⁃label study[J]. J Dermatol, 2018,45(5):529⁃539. doi: 10.1111/1346⁃8138.14294.
|
[22] |
Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial[J]. JAMA Dermatol, 2019,155(10):1153⁃1161. doi: 10.1001/jamadermatol.2019.1394.
|
[23] |
Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti⁃interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial[J]. JAMA Dermatol, 2018,154(3):309⁃316. doi: 10.1001/jamadermatol. 2017.5937.
|
[24] |
Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status[J]. JAMA Dermatol, 2016,152(7):825⁃828. doi: 10.1001/jamadermatol. 2016.0751.
|
[25] |
Storan ER, O', Gorman SM, et al. Generalized pustular psoriasis treated with ustekinumab[J]. Clin Exp Dermatol, 2016,41(6):689⁃690. doi: 10.1111/ced.12868.
|
[26] |
Daudén E, Santiago⁃et⁃Sánchez⁃Mateos D, Sotomayor⁃López E, et al. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis[J]. Br J Dermatol, 2010,163(6):1346⁃1347. doi: 10.1111/j.1365⁃2133.2010.09995.x.
|
[27] |
Palacios⁃Álvarez I, Simal⁃Gómez G, Mas⁃Vidal A, et al. Treatment of acrodermatitis continua of Hallopeau with ustekinumab as monotherapy after failure of anti⁃TNF agents[J]. J Dtsch Dermatol Ges, 2018,16(5):611⁃613. doi: 10.1111/ddg.13506.
|
[28] |
Adışen E, Özer İ, Temel B, et al. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti⁃TNF agents[J]. Dermatol Ther, 2017,30(2)doi: 10.1111/dth.12460.
|
[29] |
Saunier J, Debarbieux S, Jullien D, et al. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra[J]. Dermatology, 2015,230(2):97⁃100. doi: 10.1159/000367690.
|
[30] |
Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau[J]. J Eur Acad Dermatol Venereol, 2020,34(10):2330⁃2338. doi: 10.1111/jdv.16265.
|
[31] |
Bertelsen T, Kragballe K, Johansen C, et al. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis[J]. Int J Dermatol, 2014,53(10):e464⁃e466. doi: 10.1111/ijd.12511.
|
[32] |
Gerdes S, Franke J, Domm S, et al. Ustekinumab in the treatment of palmoplantar pustulosis[J]. Br J Dermatol, 2010,163(5):1116⁃1118. doi: 10.1111/j.1365⁃2133.2010.09897.x.
|
[33] |
Hegazy S, Konstantinou MP, Bulai Livideanu C, et al. Efficacy of ustekinumab in palmoplantar pustulosis[J]. J Eur Acad Dermatol Venereol, 2018,32(5):e204⁃204e206. doi: 10.1111/jdv.14718.
|
[34] |
Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis[J]. Expert Opin Drug Saf, 2020,19(8):969⁃980. doi: 10.1080/14740338.2020.1785427.
|